The Great Deceiver: miR-2392’s Hidden Role in Driving SARS-CoV-2 Infection
This article has been Reviewed by the following groups
Listed in
- Evaluated articles (ScreenIT)
Abstract
MicroRNAs (miRNAs) are small non-coding RNAs involved in post-transcriptional gene regulation that have a major impact on many diseases and provides an exciting avenue towards antiviral therapeutics. From patient transcriptomic data, we have discovered a circulating miRNA, miR-2392, that is directly involved with SARS-CoV-2 machinery during host infection. Specifically, we show that miR-2392 is key in driving downstream suppression of mitochondrial gene expression, increasing inflammation, glycolysis, and hypoxia as well as promoting many symptoms associated with COVID-19 infection. We demonstrate miR-2392 is present in the blood and urine of COVID-19 positive patients, but not detected in COVID-19 negative patients. These findings indicate the potential for developing a novel, minimally invasive, COVID-19 detection method. Lastly, using in vitro human and in vivo hamster models, we have developed a novel miRNA-based antiviral therapeutic that targets miR-2392, significantly reduces SARS-CoV-2 viability in hamsters and may potentially inhibit a COVID-19 disease state in humans.
Article activity feed
-
-
-
-
-
SciScore for 10.1101/2021.04.23.441024: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Ethics not detected. Sex as a biological variable not detected. Randomization not detected. Blinding not detected. Power Analysis not detected. Cell Line Authentication not detected. Table 2: Resources
Experimental Models: Cell Lines Sentences Resources Publicly available RNA-seq data: A549, Calu-3, NHBE, and COVID-19 lung biopsy: Raw RNA-seq read counts from the publication by Blanco-Melo et al. for the A549, Calu-3, and NHBE cell lines as well as post-mortem lung biopsies from two COVID-19 patients were downloaded from the Gene Expression Omnibus (series accession GSE147507) (Blanco-Melo et al., 2020). A549suggested: NoneCalu-3suggested: NonemiR-2392 mimic experiments in SH-SY5Y cells and RNA-seq: RNA was … SciScore for 10.1101/2021.04.23.441024: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Ethics not detected. Sex as a biological variable not detected. Randomization not detected. Blinding not detected. Power Analysis not detected. Cell Line Authentication not detected. Table 2: Resources
Experimental Models: Cell Lines Sentences Resources Publicly available RNA-seq data: A549, Calu-3, NHBE, and COVID-19 lung biopsy: Raw RNA-seq read counts from the publication by Blanco-Melo et al. for the A549, Calu-3, and NHBE cell lines as well as post-mortem lung biopsies from two COVID-19 patients were downloaded from the Gene Expression Omnibus (series accession GSE147507) (Blanco-Melo et al., 2020). A549suggested: NoneCalu-3suggested: NonemiR-2392 mimic experiments in SH-SY5Y cells and RNA-seq: RNA was dissolved in nuclease free water and concentration determined spectrometrically at 260nm using a Biotek plate reader (Biotek). SH-SY5Ysuggested: NoneSoftware and Algorithms Sentences Resources Publicly available Bronchial Alveolar Lavage Fluid (BALF) COVID-19 RNA-sequencing data: Fastq files were downloaded from SRA (NCBI BioProject PRJNA605907 (Shen et al., 2020) and NCBI BioProject PRJNA390194 (Ren et al., 2018)). BioProjectsuggested: (NCBI BioProject, RRID:SCR_004801)Data were then aligned using STAR (v2.7.3) two pass mode to the Human reference genome (GRCh38 v99 downloaded 04-27-2020). STARsuggested: (STAR, RRID:SCR_004463)Unaligned data were written to a fastq file, and then realigned to the GRCh38 reference genome using Bowtie 2 (v2.3.4.1), and output sam file converted to a bam file using samtools (v1.7). samtoolssuggested: (SAMTOOLS, RRID:SCR_002105)Publicly available RNA-seq data: A549, Calu-3, NHBE, and COVID-19 lung biopsy: Raw RNA-seq read counts from the publication by Blanco-Melo et al. for the A549, Calu-3, and NHBE cell lines as well as post-mortem lung biopsies from two COVID-19 patients were downloaded from the Gene Expression Omnibus (series accession GSE147507) (Blanco-Melo et al., 2020). Gene Expression Omnibussuggested: (Gene Expression Omnibus (GEO, RRID:SCR_005012)Final libraries were quantified using fluorescent-based assays including PicoGreen (Life Technologies) or Qubit Fluorometer (Invitrogen) and Fragment Analyzer (Advanced Analytics) and sequenced on a NovaSeq 6000 sequencer (v1 chemistry) with 2×150bp targeting 60M reads per sample. PicoGreensuggested: NoneResults from OddPub: Thank you for sharing your code and data.
Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.Results from TrialIdentifier: We found the following clinical trial numbers in your paper:
Identifier Status Title NCT04475601 Recruiting Enzalutamide Treatment in COVID-19 NCT04604223 Recruiting Effect of Pioglitazone on T2DM Patients With COVID-19 Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: Please consider improving the rainbow (“jet”) colormap(s) used on page 42. At least one figure is not accessible to readers with colorblindness and/or is not true to the data, i.e. not perceptually uniform.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
-